Chevy Chase Clinical Research

Chevy Chase, Maryland 20815-7313

3 studies enrolling now · 50 studies all time

What they study most

Clostridium Infections, Colitis, Ulcerative, Colonic Diseases, Colonic Polyps, Colonoscopy, Colorectal Cancer, Colorectal Neoplasms, Conscious Sedation, Crohn Disease, Crohn's Disease, Diarrhea, Digestive System Diseases

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease — Completed
• Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease — Stopped early
• A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) — Stopped early
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis — Completed
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Prevention of Recurrence of Diverticulitis — Completed
• Efficacy and Safety Study of Ozanimod in Ulcerative Colitis — Completed
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease — Completed
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome — Completed
• Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis — Completed
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea — Completed
• A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) — Completed
• An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis — Completed
• Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers — Stopped early
• A Study of MDX-1100 in Subjects With Active Ulcerative Colitis — Completed
• Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies — Completed
• Dose Escalation and Remission (DEAR) — Completed
• Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome — Completed
• Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis — Completed
• A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. — Completed
• Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis — Status unconfirmed
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy — Completed
• An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy — Completed
• Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin — Completed
• Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin — Completed
• Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease — Completed
• Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease — Completed
• Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis — Completed